Published 7 hours ago • loading... • Updated 7 hours ago

A new Lyme disease vaccine is in the works

Last week, Pfizer and French vaccine company Valneva released phase 3 clinical trial data for PF-0730740, a four-dose Lyme disease vaccine they developed together that is about 70% effective.
The regimen requires four doses over a year; the first two are administered two months apart, the third between months five and nine, and the final injection one year later.
However, the study did not meet its primary statistical endpoint, and researchers only identified the 70% effectiveness after reanalyzing the data, which has not been peer reviewed.
Infectious disease specialist Amesh A. Adalja, MD, of the Johns Hopkins Center for Health Security, says that 70% effectiveness is "fairly high" and provides "significant protection" to vaccinated individuals.
Experts note that nearly half a million Americans are diagnosed with the tick-borne illness annually, particularly in Lyme-endemic areas where the vaccine would provide the most benefit.

Insights by Ground AI